
    
      BIOFLOW-VII is a prospective, multicenter, single-arm study. Subjects with coronary artery
      disease (CAD) who undergo an on-label percutaneous coronary intervention (PCI) with a placed
      Orsiro stent within the prior 24 hours will be screened post-index procedure per the protocol
      inclusion and exclusion criteria.

      Following the index procedure and study enrollment, subjects will be followed for 5 years.
      The follow-up schedule will include an intermediate study visit at 1 month, a primary
      endpoint study visit at 12 months, and long-term study visits at 2, 3, 4, and 5 years.
    
  